Lunch Symposium: Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges

Lunch Symposium: Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges

National Meeting
Program Details

Registration for the symposium is now available. 

A Friday Satellite Symposium preceding the 61st ASH Annual Meeting and Exposition 

Hilton Orlando
Meeting Room:  Orlando Ballroom 3, Lower Level 
6001 Destination Parkway 
Orlando, Flordia 32819

December 6, 2019

12:30 PM - 1:30 PM, Registration and Complimentary Lunch Buffet
  1:30 PM - 4:30 PM, Interactive Symposium and Q&A Session


Gail Roboz, MD
Weil Cornell Medicine
New York, New York

Ajai Chari, MD
The Mount Sinai Hospital
New York, New York

Steven Coutre, MD
Stanford University Medical Center
Stanford, California

Prashant Kapoor, MD
Mayo Clinic
Rochester, Minnesota

Aaron C. Logan, MD, PhD
University of California, San Francisco
San Francisco, California

Intended Learners

Hematologists, oncologists, PAs, NPs, nurses, pharmacists, and pathologists who specialize in hematology, as well as other HCPs who care for patients with hematologic malignancies.

Learning Objectives

After completing this activity, participants should be able to

  • Compare currently-available MRD testing methods and describe their application to discrete hematologic malignancies
  • Discuss existing guideline recommendations for MRD testing and the various factors that may affect MRD test results
  • Evaluate the prognostic significance of MRD across the spectrum of hematologic malignancies
  • Identify potential future applications for MRD in real-world clinical practice
Activity Overview

Participants will obtain a pre- and post-activity survey, evaluation, and activity materials onsite. Attendees will be asked to complete the pre-activity survey before the lecture and the post-activity survey and evaluation immediately after the lecture. A faculty question-and-answer session will follow the presentation.

Instructions for Receiving Documentation of Credit

Participants are requested to complete the electronic evaluation immediately following the educational session or complete the online evaluation within 2 weeks of the event. Participants who submit an electronic evaluation onsite will receive documentation of credit via email within 8 weeks. Individuals who participate in the activity and submit the evaluation form online at will immediately receive documentation of credit.  Participants will be asked to log in or create an account at


 In support of improving patient care, this activity has been planned and implemented by the North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by ACCME, ACPE, and ANCC to provide continuing education for the healthcare team.


 Imedex is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



Imedex designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™.


Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NACCME has been authorized by the American Academy of PAs (AAPA) to award Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 3.5 AAPA Category 1 Credits. PAs should only claim credit commensurate with the extent of their participation. 


This continuing nursing education activity awards 3.50 contact hours. 

Provider approved by the California Board of Registered Nursing, Provider #13255 for 3.50 contact hours.


This live, knowledge-based activity (Universal Activity Number: JA0006201-9999-19-121-L01-P) has been approved for a maximum of 3.50 contact hours (.0350 CEUs). The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. The deadline to claim credit is February 6, 2020. Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

Planning Committee

The planning committee comprises of, Ajai Chari, MD, The Mount Sinai Hospital, New York, New York; Steven Coutre, MD, Stanford University Medical Center, Stanford, California; Prashant Kapoor, MD, Mayo Clinic, Rochester, Minnesota; Aaron C. Logan, MD, PhD, University of California, San Francisco, San Francisco, California; Gail Roboz, MD, Weill Cornell Medicine, New York, New York; 

Imedex planners and staff include Chris Bolwell and Regina Portee.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of Imedex to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty is reported the following:

Ajai Chari, MD, reports that he has nothing to disclose in relation to this activity.

Steven Coutre, MD, reports that he has a consultancy relationship with AbbVie, Astellas, AstraZeneca, Celgene, Genentech, Janssen and Pharmacyclics, has received honoraria from Janssen and Pharmacyclics, has had membership on a board of directors or advisory committee for AbbVie, Astellas, AstraZeneca, Celgene, Genentech, Janssen and Pharmacyclics, has recevied research funding from AbbVie, Acerta, Celgene, Gilead, and Janssen, has served on the data safety monitoring committee for BeiGene and has received travel, accommodations, or other expesnes from AbbVie, BeiGene, Celgene, Janssen and Pharmacyclics.

Prashant Kapoor, MD, reports that he has recevied research funding from Celgene, GlaxoSmithKline, Sanofi and Takeda, has received honoraria from Celgene and Takeda.

Aaron C. Logan, MD, PhD, reports that he has had membership on a board of directors or advisory committee for Agios, Amgen, and Incyte. 

Gail Roboz, MD, reports that she has a consultancy relationship with AbbVie, Actinium, Amphivena, Argenx, Astellas, Astex, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Janssen, Jazz, MEI Pharma, Novartis, Orsenix, Otsuka, Pfizer, Roche/Genentech, Sandoz and Takeda and has received research funding from Cellectis. 

Chris Bolwell  is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to

ADA Statement

Imedex, an HMP Company complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137. 

Grant Support

This activity has been supported through an independent educational grant from Adaptive Biotechnologies and Sanofi Genzyme.

Privacy Policy

Imedex protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. Imedex and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.